Is it safe for patients on warfarin to have invasive dental procedures?
The management of anticoagulated patients when undergoing dental treatment has been very controversial in the past. Should we alter the regime to promote coagulation following our surgical procedures, but risk life-threatening thromboembolitic events? Or deal with the prolonged bleeding or risk of haemorrhage? This is the question. There has to be a balance and this needs to take into account the gravity of the consequences of the different actions. New guidelines have been published and it is important for both dental and medical practitioners to be aware of this to improve uniformity of care and move towards an evidence-based healthcare.
Nowadays, about 0.5-1.0% of the UK population take warfarin, and this is on the rise. The most common indication for its prescription is atrial fibrillation, although it is also prescribed for many other conditions e.g. deep vein thrombosis (DVT), pulmonary embolism, prosthetic heart valves, systemic lupus erythematosus and antiphospholipid syndrome. On occasion, general dental practitioners will ask the patient's physician for advice regarding the anticoagulation regime. Often, these questions arise in light of patients having conditions with which the dentist may not be as familiar and hence extra caution is used. Therefore, physicians need to be aware of the new guidelines to manage these situations adequately.
The risk of significant bleeding in patients who are taking oral anticoagulants and have a stable international normalised ratio (INR) below 4.0 is very small. The risk of them suffering a thromboembolic event if their medication is discontinued temporarily for dental treatment is small too, but is a potentially lifethreatening risk. Fatalities due to the latter have occurred in the past and there should be no reason why it should occur nowadays.
Indeed the detailed new guidelines introduced will battle any previous misconceptions and promote uniformity of care. The British Committee for Standards In Haematology, Task Force on Haemostatis and Thrombosis, the British Dental Association and the National Patient Safety Agency have developed new evidence-based guidelines for the management of patients on oral anticuagulation. 1 Patient information leaflets have been produced as well as flow charts for dentists and these have been sent to all general dental practitioners to promote the safe and uniform management of these patients.
The Guidelines provide a detailed account of what to do and the evidence used to support the recommendations. Below is a summary of these guidelines.
General guidelines
A thorough medical history should be taken and the medications the patient is taking and the doses noted. If any of the following co-existing medical conditions are present, the patient should be referred for any dental surgical procedures to a hospital-based oral and maxillofacial surgery department due to the increased risk of bleeding; liver impairment, renal failure, thrombocytopenia, haemophilia, other haemostasis disorders, receiving chemotherapy or taking more than one antiplatelet drug.
The INR should be checked in the 72 h previous to the procedure. If the INR is below 4.0 dental procedures can be carried out in the primary care setting. The surgical skills of the primary care dentist and the difficulty of the surgery should also be taken into account when deciding where treatment should be carried out when the INR is approaching 4.0.
INR <4.0
Usually these patients can receive dental treatment in primary care setting without discontinuing or adjusting their warfarin dose.
Timing of the appointment: Ideally at the beginning of the week and in the morning, to manage any bleeding complications during the working day and week.
Antibiotic cover required? If required, current guidelines in the British National Formulary should be followed for prescription of appropriate antibiotic cover, taking into account any drug interactions.
Local anaesthesia: Use local anaesthetic containing a vasoconstrictor and if possible avoid Inferior alveolar blocks. If the latter is required, it should be given slowly and with an aspirating syringe.
For extractions use local haemostatic measures: prolonged bleeding (compared with patients who are not on anticoagulants) may occur but is usually controlled by local measures, such as pressure, absorbable oxidized cellulose (Surgicel), collagen sponges and sutures. Tranexamic acid mouthwash (5%) can also be used (four times a day for 2 days), however, this is not as readily available in dental primary care settings and dentists cannot prescribe it.
Postoperative instructions to be given to the patient for control of bleeding and pain. Advise patient to take paracetamol as an analgesic and to avoid NSAIDS (aspirin, ibuprofen, diclofenac). Codeine is not used in dental analgesia and antibiotics should not be prescribed routinely on this group of patients.
INR >4.0
Refer patient to anticoagulation service.
Reschedule procedure for when INR <4.0 If INR remains above 4.0 or is erratic, the patient should be referred to specialist services for dental treatment.
Advice to be given to the patient
There is a leaflet available for patients who are on anticoagulation therapy 'Oral Anticoagulant therapy: Important Information for dental patients', which was produced by the National Patient Safety Agency and distributed to dental surgeries. This leaflet mainly advises patients to tell their dentists about their anticoagulation medication, provides postoperative instructions for dental extractions and advice on how to control postoperative bleeding.
Caution with warfarin's drug interactions!
Certain drugs should not be prescribed to patients taking warfarin due to the adverse interactions. The following drugs could cause over-anticoagulation and haemorrhage, hence should be AVOIDED: metronidazole, miconazole, erythromycin and NSAID's (e.g. ibuprofen, aspirin, diclofenac).
Metronidazole should be avoided. If this is not possible, the new guidelines suggest contacting the General Practitioner or anticoagulant clinic. The warfarin dose may need to be reduced by a third to a half, additional INR testing carried out and readjustment of the warfarin dose will be required following finalization of the antibiotic course.
There have been some anecdotal reports regarding the interaction of amoxicillin with warfarin; however, the present guidelines suggest that there have been no incidents with 3 g given for antibiotic prophylaxis. More caution may be required with macrolide antibiotics (erythromycin, azithromycin) because these interact unpredictably with warfarin and only in certain patients. In both cases, patients should be advised to be vigilant for increased bleeding. 
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